Edition:
United Kingdom

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

230.65USD
20 Jun 2018
Change (% chg)

$0.63 (+0.27%)
Prev Close
$230.02
Open
$229.77
Day's High
$231.17
Day's Low
$229.77
Volume
14,605
Avg. Vol
343,584
52-wk High
$248.20
52-wk Low
$191.53

Select another date:

Fri, May 11 2018

Photo

U.S. investigates bloodstream infections for link to heparin syringes

SHANGHAI/CHICAGO Health agencies are investigating an outbreak of bloodstream infections in children from four U.S. states that may be linked to heparin and saline syringes made by Becton Dickinson and Co, the agencies told Reuters. The U.S. Centers for Disease Control and Prevention has confirmed 14 cases of bloodstream infections in children caused by the same strain of the Serratia marcescens bacterium, the agency's lead investigator on the outbreak said in a telephone interview.

U.S. investigates bloodstream infections for link to heparin syringes

* 14 children in 4 states have confirmed bloodstream infections

BRIEF-Becton Dickinson Reports Q2 Loss Per Share $0.19

* BD ANNOUNCES RESULTS FOR 2018 SECOND FISCAL QUARTER; RAISES FISCAL 2018 GUIDANCE

BRIEF-Becton Dickinson Files For Potential Mixed Shelf Offering

* BECTON DICKINSON AND CO FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text (https://bit.ly/2HvryvV) Further company coverage:

BRIEF-Becton Dickinson Updates Instructions for Use for Certain BD Vacutainer Blood Collection Tubes

* BECAME AWARE OF CONCERNS ABOUT INACCURATE LEAD TEST RESULTS FROM MAGELLAN DIAGNOSTICS LEADCARE TESTING SYSTEMS

BRIEF-Becton, Dickinson To Divest Remaining Investment In Vyaire Medical

* BD TO DIVEST REMAINING INVESTMENT IN VYAIRE MEDICAL TO FUNDS MANAGED BY APAX PARTNERS

BRIEF-Becton Dickinson Launches Circulating Cell-Free DNA Blood Collection Tube in Western Europe

* BD LAUNCHES CIRCULATING CELL-FREE DNA BLOOD COLLECTION TUBE FOR CANCER AND NON-INVASIVE PRENATAL TESTING APPLICATIONS

BRIEF-Becton Dickinson Files For Offering EUR 300 Mln Add. 0.368% Notes

* BECTON DICKINSON AND CO FILES FOR OFFERING EUR 300 MILLION AGGREGATE PRINCIPAL AMOUNT OF ADDITIONAL 0.368% NOTES DUE 2019 - SEC FILING

BRIEF-Becton Dickinson Says Received Pre-Market Approval From FDA For BD Onclarity HPV Assay

* FDA APPROVES NEW HPV TEST THAT DETECTS AND IDENTIFIES HPV GENOTYPES THAT PUT WOMEN AT HIGH RISK FOR CERVICAL CANCER Source text for Eikon: Further company coverage:

BRIEF-Becton Dickinson Q1 Loss Per Share $0.76

* BD ANNOUNCES RESULTS FOR 2018 FIRST FISCAL QUARTER; PROVIDES FISCAL 2018 GUIDANCE UPDATED FOR INCLUSION OF BARD

Select another date: